J. Miroir
Centre Jean Perrin(FR)
Publications by Year
Research Areas
Head and Neck Cancer Studies, Head and Neck Surgical Oncology, Salivary Gland Tumors Diagnosis and Treatment, Cancer Diagnosis and Treatment, Advanced Radiotherapy Techniques
Most-Cited Works
- → Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial(2022)168 cited
- → Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study(2020)126 cited
- → Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)(2020)92 cited
- → LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial(2021)78 cited
- → Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial(2023)51 cited
- → Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers(2021)28 cited
- → Délinéation des adénopathies et aires ganglionnaires pour les cancers de la sphère ORL(2014)25 cited
- → Unilateral or bilateral irradiation in cervical lymph node metastases of unknown primary? A retrospective cohort study(2019)20 cited
- → Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).(2018)19 cited
- → 854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial(2024)16 cited